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Protein in crystal form is at an extremely high concentration
and yet retains the complex secondary structure that deﬁnes
an active protein. The protein crystal itself is made up of a
repeating lattice of protein–protein and protein–solvent
interactions. The problem that confronts any crystallographer
is to identify those interactions that represent physiological
interactions and those that do not. This review explores the
tools that are available to provide such information using the
original crystal liquor as a sample. The review is aimed at
postgraduate and postdoctoral researchers who may well be
coming up against this problem for the ﬁrst time. Techniques
are discussed that will provide information on the stoichio-
metry of complexes as well as low-resolution information on
complex structure. Together, these data will help to identify
the physiological complex.
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1. Introduction: why do we need to know about
complexes?
‘No man is an island’ (John Donne, 1573–1631). Biology
thrives through interactions, from the interactions between
organisms that make up the biosphere to the interactions
between molecules and atoms in the cell. A complete
knowledge of these complex associations has the potential to
allow us to understand nature. It is the central aim of biology
to attain that knowledge.
Of all these biological interactions, perhaps the hardest for
the ‘man on the street’ to understand are those he cannot see.
These interactions (between cells, molecules and atoms) have
been the objective of biological research for only a hundred
years and already much progress has been made. One of the
most revolutionary developments of the past ﬁfty years has
been the development of techniques that allow us to ‘look’
directly at these interactions by peering into the very workings
of life itself. The trailblazer in this study has been protein
X-ray crystallography. Since Max Perutz determined the
structure of haemoglobin (Perutz, 1954) and John Kendrew
that of myoglobin, the structures produced by X-ray crystallo-
graphy have intrigued scientists across disciplines. X-ray
crystal structures of proteins have not only shown us the
beautiful convoluted shape of the peptide backbone, but have
also provided information on their interactions.
In the early days, the number of monomers in the complex
was generally already well established by biochemical and
biophysical studies, making the interpretation of the associa-
tions in the crystal a trivial exercise. As more structures were
solved, more complexes were determined, but the technicallydifﬁcult nature of X-ray crystallography meant that again most
of these were well studied in solution and hence the physio-
logical relevance of the complex was easily determined.
However, during the later part of the last century the tech-
nology and protocols used for X-ray crystallography improved
and the number of proteins crystallized increased rapidly. It
has now become the case that proteins are being crystallized
using high-throughput techniques (Terwilliger et al., 2003;
Pusey et al., 2005) with only limited biophysical and bio-
chemical characterization of the protein sample. This has led
research papers
18 Dafforn   Protein complexes Acta Cryst. (2007). D63, 17–25
Figure 1
The process of crystallization may select nonphysiological protein associations. (a) The physiological state of the protein is a dimer and the dimer can be
crystallized to provide a structure. (b) The physiological state of the protein is a dimer. The dimer cannot pack into a lattice to produce a crystal, but the
monomer alone can. Therefore, the crystal structure contains the nonphysiological state. (c) and (d) demonstrate an analogous case where the
physiological state is a monomer. For clarity, the physiological oligomerization state is circled.to the current situation where, in order to determine the
biologically relevant complex in a crystal, the scientist has had
to return to the techniques of biophysics (Perugini et al., 2005).
One approach to determining the ‘real’ oligomerization state
of a protein in a crystal structure has been through compu-
tational analysis. Computational biologists have developed a
number of algorithms that have the potential to differentiate
between physiological and nonphysiological interactions in a
crystal (Janin et al., 1988; Wang & Janin, 1993; Janin & Rodier,
1995; Henrick & Thornton, 1998; Robert & Janin, 1998;
Bahadur et al., 2004). These algorithms, although important as
an indicator, are still not completely reliable. Thus, biophysical
and biochemical characterization of protein is essential for
determination of protein association states. This review aims
to summarize these techniques.
The review provides an overview of the techniques that are
available to examine protein–protein associations. Although
many techniques exist for such studies, I have concentrated on
those that can be applied to the samples used in crystal trials.
Hence I have not included the most sensitive techniques as, in
general, signiﬁcant quantities of protein are available.
To begin, Iwill discuss why complexes in protein crystals are
not always those that are relevant in physiology. I will then
address the outwardly simple task of determining just how
many monomers make up the physiological complex. Thirdly,
I will look at a situation where the overall order of the asso-
ciation is unimportant, but where the crystal presents us with a
number of possible monomer–monomer orientations which
must be distinguished.
2. Why do complexes in crystals not match complexes
in biology?
As has been discussed in the previous section, understanding
the formation of protein complexes has two direct implications
on our understanding of biological systems. So why, if an X-ray
crystal structure of a protein provides the coordinates of all
the non-H atoms in a protein, can we not always determine the
stoichiometry of a protein complex? Surely it should be as
simple as counting how many monomeric units are in close
contact with one another?
If we take a step back and think about the crystal and
crystallization process, then the answer is clear. The conditions
for crystallizations are designed to induce protein–protein
interactions which will result in a crystal, which after all is the
‘mother of all protein complexes’. This is immediately going to
cause us problems, as a crystal structure is likely to contain
protein–protein interactions that are not physiologicalbut that
are stabilized through crystal packing. A limited study of the
PDB by Bahadur and colleagues has shown more than 100
protein dimers in the database for proteins that are monomers
in solution (Bahadur et al., 2004).
If we examine the process that leads to the production of a
protein crystal, then another potential ﬂaw in the process can
be appreciated. If we think of a dimeric protein complex, what
we must remember is that this is an equilibrium between the
monomer state and the dimer state (Fig. 1). The equilibrium
position is determined by the afﬁnities of the monomeric units
for each other.
If the dimer is able interact with other dimers in the crystal-
lization liquor to form an ordered three-dimensional associa-
tion, then a crystal will form containing the dimer. However, it
is possible that the dimer in the liquor cannot propagate to
form a crystal. In the simplest case this leads to no crystals, a
disappointed crystallographer and no structure. However, as
the process is in equilibrium, it is possible that some free
monomer exists. This is particularly possible given the
nonphysiological solution conditions in most crystallization
screens. The free monomer could associate with other
monomers in a manner that does not form a physiological
dimer. This association could propagate to form a crystal, in
this case without a physiological association.
3. What changes upon complex formation?
If it is the aim of a study to examine the potential oligomeric
state of a new protein, then it is worth, for a moment,
considering the consequences of protein oligomerization.
Such consideration will allow potential signals of complex
formation to be identiﬁed. The most obvious of all physical
changes that accompany the formation of a complex is an
increase in the molecular weight of the particles in solution.
Theoretically, all that is required to characterize an associating
system is to measure this molecular weight over a range of
particle concentrations. Analysis of these data will provide the
order of the oligomerization mechanism (e.g. monomer–dimer
or monomer–dimer–tetramer etc.) as well as afﬁnities for each
step. Such information is obtainable (notably using analytical
ultracentrifugation) and provides the greatest opportunity for
the complete characterization of a system. However, a number
of other physical characteristics can also be inherently linked
to the formation of oligomers. The binding of one monomer to
a second will lead to a reduction in solvent accessibility of the
monomer–monomer binding site. On occasions, this change
can be exploited to measure complex formation. For example,
if the formation of dimers results in burial of hydrophobic
surfaces, then a dye (such as ANSA) which changes its spec-
troscopic character when in contact with a hydrophobic
surface can be used to monitor association (Dafforn et al.,
1999). The docking of one monomer to another can also alter
the environment of amino acids on the common surface. This
disturbance can be detected using ﬂuorescence, near-UV
circular dichroism (CD; Zsila et al., 2004; Patel et al., 2006) or
nuclear magnetic resonance (NMR; Hewitt et al., 1999; Lucas
et al., 2003; Zartler et al., 2003). If those residues are aromatic
residues such as tryptophan, phenylalanine or tyrosine, then
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formation of complex (Owen et al., 1999; Lakowitz, 2006).
Formation of a complex can also induce larger changes in the
monomer architecture, leading to changes in backbone
conformation. These types of changes can be measured using
far-UV CD (Kelly & Price, 2000; Misenheimer et al., 2003),
Fourier transform infrared (FTIR) (Cooper & Knutson, 1995;
Jackson & Mantsch, 1995) spectroscopy or NMR. In some
cases, these changes have functional implications; for instance,
altering the activity of an enzyme. In these cases, simple
enzyme assays can be employed to provide information on
oligomerization.
4. How many monomeric units are in the physiological
complex?
As mentioned earlier, in the context of crystallography it is
often important to determine the true stoichiometry of a
complex in solution in order to understand the structure
present in the crystal structure. Solving this problem seems
like a relatively trivial exercise and many crystallographers
maintain that ‘careful’ examination of the crystal structure will
yield the physiologically relevant oligomer. However, there is
now a groundswell of opinion that in a signiﬁcant number of
cases the declared oligomeric structures in the PDB database
are nonphysiological (Bahadur et al., 2004). In the event that a
researcher does set out to determine the solution composition
of a protein complex, the methods available are relatively
limited. The most popular approach to this problem is
invariably size-exclusion chromatography (SEC). SEC utilizes
a porous chromatographic matrix which allows particles
smaller than the pore size to partition into a larger space than
particles larger than the pore size (for an excellent review of
the details of SEC, see Winzor, 2003). This means that large
particles traverse the column bed more rapidly than small
particles, leading to a separation by size. Size-exclusion
chromatography has the main advantage that it is relatively
cheap and is easy to carry out. However, as is often the case,
apparent simplicity in fact belies a very complex process with
many factors that can lead to erroneous results. An idealized
SEC matrix is utterly inert, allowing no interaction between
the particles in solution and itself. Why does this make an ideal
matrix? If a particle is able to interact with the matrix, its ﬂow
through the column will be retarded (Fig. 2). This retardation
will then be erroneously interpreted as a lower relative
molecular weight than the true one. Manufacturers have
worked hard to reduce these interactions by reducing the
charge density of the column to a minimum etc. However, the
highly variant chemical nature of protein surfaces makes them
very effective at adhering to a range of materials. In many
cases, the buffer conditions used during the SEC experiment
can be altered to reduce interactions with the column. A
common approach is to increase the ionic strength as this
reduces charge–charge interactions with the column matrix.
However, it must always be borne in mind that increasing the
ionic strength also has the potential to alter the interactions
between the monomers of any complexes. Indeed, if the
interaction is charge–charge-based then the complex may
dissociate completely. Fortunately, most protein–protein
interactions have a signiﬁcant involvement of hydrophobic
interactions, reducing the effect of changes in ionic strength. If
a rigorous analysis of the effect of matrix interaction is
required, then the experiment should be run at a range of ionic
strengths. A plot of apparent weight versus ionic strength
should then indicate the reliability of weight determined. If
the weight is unchanged by ionic strength, then it is likely to be
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Figure 2
A comparison of data from SEC (a) and AUC (b) on the same protein. SEC provides a weight that is close to that expected for a dimer, whereas AUC
shows a peak for the weight of a tetramer. It is likely that the result using SEC indicates that the protein (which is membrane-associated) interacts with
the column matrix, leading to retardation and an erroneously low estimation of weight.correct. If the weight increases, then it is likely that the protein
is interacting with the column (or the increase in ionic strength
is stabilizing a higher order association). If the weight
decreases, then it is likely that the protein oligomer is held
together by ionic interactions (and is unlikely to be observed
in the high ionic strength solutions used for crystallography).
In the two preceding cases, if the plots of apparent weight
versus ionic strength plateau (at high ionic strength in the
former and lower in the latter), then the weight value at the
plateau will be closer to the correct value.
Even if interactions with the chromatographic matrix are
not an issue, the experimentalist also has to take into account
other issues which may lead to incorrect weights from SEC. It
is common to erroneously view a protein complex as a ‘solid’
unchanging entity. It must be remembered that the monomers
within the complex are in fact in a state of continuous
exchange with free monomers in solution. This exchange rate
is different for different complexes and is related to the afﬁ-
nity monomers have for each other in a complex. This
exchange can have large effects on the observed weight as
measured by SEC. Complexes where the exchange is slow
compared with the time taken to perform an SEC experiment
(and the monomer–monomer afﬁnity is high) will provide a
weight that is consistent with the weight of the complex.
However, as the exchange increases (and the afﬁnity drops)
the apparent weight determined by the SEC begins to reduce
towards that of the monomer. This can lead to an under-
estimation of the number of monomers in the complex. To
negate this effect, SEC should be performed on a range of
protein concentrations. If the exchange is slow (and the
monomer–monomer afﬁnity high) then the weight should not
change considerably with concentration. However, if the
exchange is fast (and the afﬁnity low) the weight will decrease
with concentration. As with the effect of ionic strength, if the
plot forms a plateau at high concentrations, this weight may be
taken as that of the complex.
The ﬁnal issue with determination of weight by SEC is that
of molecular shape. All SEC measurements are made with
reference to measurements made using a ‘standard’ set of
proteins. In most cases, these are commercial samples and are
chosen to have negligible interactions with the matrix and to
be close to an ideal spherical shape. Use of these references is
adequate if the protein (and the complex) you are studying is
also close to spherical; however, as the protein structure
deviates from this idea, the apparent weight becomes less
reliable. This effect can become extreme where monomers and
oligomers of a protein are rod-like (Millard et al., 2005). In
these cases, results from SEC are usually untrustworthy.
As can be seen, SEC, although simple in concept, suffers
from a number of fundamental problems when it comes to
determining oligomerization states. It is not the case of a single
run using SEC providing a deﬁnitive answer. Such studies
should as a minimum involve a number of experiments at a
range of protein concentrations. Ideally, a plot of ionic
strength versus apparent molecular weight should also be
undertaken. This is a particularly lengthy process as the set of
reference proteins also has to be run at each of the ionic
strengths. However, taking all these issues into consideration,
SEC often provides accurate assessments of protein oligo-
merization and should not be discounted as a very useful
technique.
The inadequacies of SEC discussed in the previous section
leads a researcher to ask the question: what other methods are
there? In this section, I will discuss some of the other tech-
niques that exist for determination of solution molecular
weight. Unlike SEC, the techniques described below measure
the molecular weight of a protein in a solution in a sample
chamber where the molecular-weight measurement is being
made by an instrument or device that is able to ‘interrogate’
the sample. The requirement for complex instrumentation
makes these techniques more costly than a simple SEC setup,
but in many cases the quality and reliability of the data
produced matches the cost.
To keep within the size limitations of this review, I will limit
my discussion to the two techniques most commonly
encountered in bioscience, dynamic light scattering (DLS) and
analytical ultracentrifugation (AUC).
Dynamic light scattering (also called quasi-elastic light
scattering or photon correlation spectroscopy) relies on the
observation that the scattering observed from particles in a
ﬂuid ﬂuctuates (or ﬂickers) with time (for reviews of the
experimental and theoretical details, see Schmitz, 1990;
Brown, 1993; Johnson & Gabriel, 1994). This phenomenon can
be observed in real life by observing the ﬂickering caused by
dust particles in a beam of sunlight. DLS uses a combination
of a monochromatic laser light source and a high-speed
detector to measure the scattering ﬂuctuations in a sample
solution with time. These data are then deconvoluted to
produce a weight distribution. The deconvolution relies on the
observation that particles in solution are constantly moving
owing to random impacts with the particles that make up the
ﬂuid. Einstein and Stokes were able to show that the motion of
these particles is dependent on a relatively simple relationship
RH ¼ kT=6  D
where T is temperature, k is the Boltzmann constant, D is the
diffusion coefﬁcient and   is the solution viscosity and the
radius of the particle is RH.In a typicalDLS experiment, T and
  are known. This allows the solution molecular weight to be
calculated from a measurement of D using DLS. DLS can also
provide an indication as to which solution conditions will allow
crystallization (Mikol et al., 1990; Skouri et al., 1991; Wilson,
2003).
Actually making a DLS measurement requires a few prac-
tical issues to be taken into account. In general, the sensitivity
of DLS is such that at least a 0.25 mg ml
 1 solution of a typical
50 kDa protein is required to provide a good signal. The
concentration required is directly related to the weights of the
protein, with lower molecular-weight molecules requiring
higher concentration and higher molecular-weight molecules
requiring a lower concentration. In the case of samples that
have been used for crystallographic studies, this is not usually
a problem. Perhaps the greatest limiting factor when it comes
to using DLS is the purity of the sample. The deconvolution of
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only detect the presence of two or fewer species in solution.
Any more than this and deconvolution of the data becomes
more difﬁcult and gaining more meaningful results less likely.
Samples used for crystallography are usually of a high enough
quality that this is not a problem. However, care should be
taken to ﬁlter the sample before use to remove the large
particulates often found in laboratories such as dust, miscel-
laneous ﬂuff and hairs. We have had most success with 0.3 mm
pore-size ﬁlters and this simple step can make the difference
between a measurable and an unmeasurable sample. The data
from the DLS usually comes in the form of a table that
contains the molecular weight and radius of gyration of the
species and its relative abundance in solution. One factor that
has to be taken into account when using DLS is that, like SEC,
it relies on the assumption that the shape of proteins
approximates to a sphere. If this is not the case, then the
mathematical model that is used in the calculation is incorrect.
Unlike SEC, it is possible in many of the manufacturers’
software packages to alter the model to take into account
other shapes, e.g. rod, ellipse etc.
Analytical ultracentrifugation (AUC) is probably the ‘gold
standard’ when it comes to determination of biomolecular
oligomerization but comes at a considerable cost. However,
the information gained from AUC can stand alone and in
many cases an AUC study yields a plethora of other data that
tell us more than just the oligomerization state. Analytical
ultracentrifugation determines the solution molecular weight
of particles by measuring their motion within a centrifugal
ﬁeld (for detailed reviews of the technical aspects, see Schuster
& Toedt, 1996; Minton, 2000; Lebowitz et al., 2002). The ﬁeld is
induced by spinning the sample and the motion of the particle
is measured either by relying on the absorbance of light by
chromophores within the particle or by using laser inter-
ferometry. AUC allows the motion of the particles to be
examined in two ways. A sedimentation-velocity (SV)
experiment measures the velocity with which particles move
out from the centre of the rotor, eventually sedimenting at the
bottom of the rotor. A sedimentation-equilibrium (SE)
experiment is carried out at a lower speed that does not cause
complete sedimentation. Instead, the particles distribute
themselves as a gradient within the cells.This equilibrium state
is reached when the centrifugal force is balanced by a reverse
force induced by the concentration gradient within the cell.
A combination of the two experiments is extremely useful
in the study of self-association as each provides subtly
different information. A sedimentation-velocity (SV) experi-
ment is a more rapid experiment than an SE experiment,
taking approximately 8 h compared with days. Analysis of
sedimentation velocity provides information on the size
distribution of particles in a sample. The data from an SV
experiment looks similar to an SEC trace, the only difference
being that units for the axis of an SV distribution plot are
generally quoted in terms of the sedimentation coefﬁcient. In
cases where the solution contains a relatively small number of
species, this distribution plot can be transformed so that the x
axis is represented in terms of weight. However, like all the
previous techniques, results from SV can be distorted if the
particles diverge from a spherical shape. Unlike the other
techniques, SV analysis also returns an estimation of the
spherical nature of the sample in terms of the frictional ratio.
This ratio ranges from 1 (sphere) upwards as the particle
becomes more elongated. With this in mind, it is still possible
to obtain a good estimation of weight from SV and in a
number of cases we have achieved results within 1% of the
sequence weight (Fig. 2). In common with the other tech-
niques discussed above, if the particle is in a complex the
weight that is measured by the AUC in SV mode is deter-
mined by the exchange rate and afﬁnity of the monomeric
units for one another. Like the other techniques, this effect
can be checked for by using a range of concentrations. In many
cases, each AUC experiment can accommodate eight samples,
allowing seven concentrations to be analysed simultaneously
(the eighth sample is a reference cell). When this is combined
with an absorbance-based detection system, data on a wide
range of concentrations can be collected (typically 0.1–
100 mM).
If an associating system is suspected and a clear answer is
not gained from an SV experiment, then an SE experiment is
probably required. These experiments are quite lengthy and
require that the protein is stable over a number of days at
278 K. As mentioned earlier in this article, an SE experiment
produces a continuous concentration gradient of the particle
in the sample chamber. For a non-associating system, the
shape of the concentration gradient can be analysed to
provide a surprisingly accurate solution weight (typically
within 0.1%). For an associating system, the situation is more
complex. If we consider a single AUC cell where the
concentration is low (the end near the axis of the rotor), the
law of mass action dictates that solution will tend to contain a
higher concentration of monomeric material. Where the
concentration is at its highest (the end furthest from the
rotor), association is favoured, a decreased proportion of
monomeric material will be found and the complex will be
populated instead. The entire cell as a whole contains a
continuum between and including these two extremes. These
distributions can be analysed successfully to yield both the
oligomeric weight (and hence the number of monomers in the
oligomer) and often the equilibrium constants for the oligo-
merization reaction. However, analysis of this type of data is
complex and requires some prior knowledge. Firstly, an
accurate weight is needed for the monomer (not usually a
problem if the sequence is known, but post-translational
modiﬁcations can be an issue). An idea is also needed of what
the order of the resulting oligomer is (dimer, trimer, tetramer
etc.). This piece of information causes something of a dilemma,
because if we knew this then we would not be doing AUC. To
some extent, this logical impasse can be circumvented by
analysing the data using a range of models for different
possible oligomerization states. In general, one of the models
will ﬁt much better than any of the others, indicating the
correct answer. It should be noted that such computational
ﬁtting approaches are often improved by increasing the
amount of data available to be ﬁtted. For SE AUC, it is
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Figure 3
The use of FRET to determine the correct dimer structure for  1-
antitrypsin (Sivasothy et al., 2000). (a) Models showing three possible
dimer structures: I, II and III. The residues upon which ﬂuorophores are
attached are shown in dimer I. (b) The ﬂuorescence of a donor
ﬂuorophore in the presence of an acceptor ﬂuorophore is measured
under conditions that promote and disrupt polymerization. FRETresults
in a decrease in the ﬂuorescence from the donor ﬂuorophore. A range of
FRET signals are measured for proteins with ﬂuorophores at different
positions on the surface of  1-antitrypsin. These are then used to model
the structure of the dimer. The correct dimer is dimer III.
convention to make measurements for at least three different
starting concentrations. Modern ﬁtting routines allow data
from all these experiments to be globally ﬁtted, resulting in
lower errors.
5. Which complex is the physiological one?
Having now used the techniques detailed above to determine
the number of monomeric units in the physiological complex
and having identiﬁed the correct complex using the crystal
structure, many would say that this was the end of the
procedure. However, how do we know that the complex in the
X-ray structure represents the physiological complex? Just
because the biophysics indicates a dimer and we can identify a
likely dimer in the structure, this does not mean that that is the
physiologically relevant dimer. As discussed earlier, within a
crystallization drop a number of processes are competing with
one another. On one hand there is competition between the
processes of crystallization and aggregation. However, of
more interest to us is the process that dictates the growth of a
viable crystal. In this case, ordered interactions are the key.
Consider a situation where all possible ordered arrays of a
dimer produce structures that cannot propagate to form a
large crystal. If, however, as we previously considered, a small
proportion of monomer is present in solution (this proportion
can be enhanced by solution conditions in the drop, see
earlier), then in this case the monomer may associate in an
ordered fashion, leading to a crystal. The important point is
that this crystal does not contain the physiological complex.
However, it is quite possible that in the crystal lattice contacts
between monomers could lead a researcher to conclude that a
dimer (the wrong dimer) does exist. So the question is: how do
we know which is correct? Thankfully, there are often
biochemical reasons that indicate whether a complex is thecorrect one; for example, if the complex contains a ligand in an
active site that is known to be composed of two monomers. In
other cases, the structure will agree with other structures of
similar proteins that have been conﬁrmed to be physiological.
Alternatively, if the interface between the two monomers is
very hydrophobic, it indicates that it is likely to be unstable if
exposed. In some cases, however, none of this evidence exists.
In this case, we have to resort to biochemical or biophysical
measurement (for a review of the use of ﬂuorescence in such
studies, see Yan & Marriott, 2003).
Unfortunately, unlike determining the number of mono-
mers in a complex, there are no universal methods for deter-
mining which complex is the correct one. Often, examination
of the structure will suggest an experiment. For example, if a
protein contains a single tryptophan that is on the interface
between monomers, then it would be expected that this
tryptophan will change intensity and emission maximum upon
complex formation. Another method is to chemically cross-
link the monomers in the complex and then to determine the
cross-link position using mass spectrometry. There are many
other techniques; however, I would like to detail one tech-
nique that has been successfully used on a number of occa-
sions: ﬂuorescence resonance energy transfer (FRET).
Fluorescence resonance energy transfer is a physical
phenomenon which can be used to measure the distances
between points on a nanometer scale (for a detailed discussion
of FRET and many other ﬂuorescence techniques, see
Lakowitz, 2006). The FRET reaction requires the use of two
ﬂuorescent probes that have overlapping spectra (the emission
spectrum of one overlaps the excitation of the other;
Giepmans et al., 2006). When these two ﬂuorescent probes are
close to each other (typically <100 A ˚ ), FRET can occur. The
FRET process involves the absorption of a photon by one of
the probes: that with the lower wavelength absorbance
maximum. An electron in the probe is promoted to a higher
energy state, which then collapses. In the absence of the
second probe, the collapse leads to the emission of a photon of
lower energy (ﬂuorescence). However, with a second ﬂuoro-
phore nearby, the energy can be transferred nonradiatively to
the second ﬂuorophore. An electron in the second probe is
then promoted to a higher level which then collapses, giving
rise to a photon with an energy (emission maximum) consis-
tent with the properties of the second probe. The key to this
process is that the efﬁciency of the transfer process is ex-
tremely sensitive to the distance between the two probes.
Therefore, if we measure the efﬁciency, we can calculate the
distance. If a number of these measurements can be made
between monomers in a complex, then these can be combined
with the information in the crystal structure to produce a
structure of the complex. We have used such a system to
determine the structure of an oligomer of a member of the
serpin superfamily of proteins,  1-antitrypsin (Sivasothy et al.,
2000).
Our study of  1-antrypsin was initiated by the publication of
three structures that showed serpin dimers (Fig. 3a), each with
quite different monomer–monomer interfaces. Each structure
seemed to have merits with regard to what was known about
the physiological dimer and there seemed to be no simple
biochemical test that would prove that one structure was
correct in comparison with the others. To address this
problem, we constructed four  1-antrypsin mutations, intro-
ducing asinglecysteine in placeof a surface serine in each case
(we had previously deleted the only natural cysteine in  1-
antrypsin). These mutants were puriﬁed and labelled with
tetramethylrhodamine iodoacetamide (TMRIA) or ﬂuor-
escein iodoacetamide (IAF). Together, these two dyes can
participate in FRET, with IAF acting as a donor ﬂuorophore
and TMRIA as an acceptor (Fig. 3b). After labelling, we were
left with eight labelled proteins: four mutants each with either
of the two labels. These were used in a FRETexperiment. To
begin with, a donor- and an acceptor-labelled pair of proteins
were mixed and the ﬂuorescence spectra of the donor and
acceptor were measured. Serpin polymerization requires
incubation at elevated temperature, which meant that this
experiment could act as a baseline measurement as no inter-
action would exist between the two species of  1-antrypsin.
The mixture was then left to polymerize for 24 h at 318 K and
a second set of spectra were measured. Changes in donor and
acceptor ﬂuorescence were then calculated and used to
determine the distance between the two probes. FRET data is
related to distance data by
R ¼ð 1=E   1Þ
1=6R0; ð1Þ
where R is the distance between the ﬂuorophores, E is the
efﬁciency of FRET (ranging from 1 to 0) and R0 is the Fo ¨rster
radius for the ﬂuorophore pairs used and is deﬁned by
R0 ¼½ ð 8:79   10
 5Þ 
2n
 4’DJDA 
1=6; ð2Þ
where  
2 is the orientation factor which is assumed to be 2/3
for a freely rotating ﬂuorophore, n is the refractive index (1.4
for water) and ’D is the quantum yield of the donor ﬂuoro-
phore. ’D can be obtained by measuring the ﬂuorescence
intensity of the donor ﬂuorophore compared with a standard
solution of sodium ﬂuorescein (10
 6 M in 0.01 M NaOH pH
12, ’ = 0.79). JDA is the spectral overlap for the two ﬂuoro-
phores and is 0.5 M
 1 cm
 1 nm
4 for TMRIA and IAF.
The procedure was repeated with eight other pairs. The
probe–probe distances could then be compared with similar
distances calculated from the available crystal structures,
taking into account the added length of the probe. The result
of this study was a structure that showed that a surface loop on
 1-antrypsin inserted into a vacant  -strand position in a large
 -sheet in a second  1-antrypsin molecule. This structure
agreed well with one of the crystal structures of  1-antrypsin,
suggesting that the other structures were the result of the
crystallization process.
The approach detailed in the previous section can poten-
tially be applied to any protein complex as long as a ﬂuor-
escent probe can be inserted into the structure. I have detailed
the use of cysteine-linked probes, but probes can also be
attached to the protein N-terminus or to lysine residues with
relative ease. It is also possible to use the presence of tryp-
tophan residues if a single one exists in one of the pairs.
Tryptophan can act as a donor, with a dansyl group acting as a
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2004). It should be noted that I have also shown the use of
ﬂuorescent intensities for providing a measure of FRET efﬁ-
ciencies. However, this method can be error-prone if a control
of non-interacting monomers is not available. FRET efﬁ-
ciencies can also be determined by measurements of the rate
of ﬂuorescence decay. This method requires more complex
spectrometers that can measure ﬂuorescence decays over a
period of nanoseconds, but is becoming more popular.
6. Summary
I hope that within this review I have highlighted some of the
biochemical/biophysical techniques that can be used to
understand oligomerization states in X-ray crystal structures. I
also hope that I have highlighted the need to undertake such
studies. It is not just a case of using these techniques when the
X-ray structure is in some way ambiguous. In an ideal world,
the determination of the oligomerization state in solution
would be carried out routinely.
References
Bahadur, R. P., Chakrabarti, P., Rodier, F. & Janin, J. (2004). J. Mol.
Biol. 336, 943–955.
Brown, W. (1993). Dynamic Light Scattering: The Method and Some
Applications. Oxford: Clarendon Press.
Cooper, E. A. & Knutson, K. (1995). Pharm. Biotechnol. 7, 101–143.
Dafforn, T. R., Mahadeva, R., Elliott, P. R., Sivasothy, P. & Lomas,
D. A. (1999). J. Biol. Chem. 274, 9548–9555.
Gettins, P. G. & Olson, S. T. (2004). Methods, 32, 110–119.
Giepmans, B. N., Adams, S. R., Ellisman, M. H. & Tsien, R. Y. (2006).
Science, 312, 217–224.
Henrick, K. & Thornton, J. M. (1998). Trends Biochem. Sci. 23,
358–361.
Hewitt, C. O., Eszes, C. M., Sessions, R. B., Moreton, K. M., Dafforn,
T. R., Takei, J., Dempsey, C. E., Clarke, A. R. & Holbrook, J. J.
(1999). Protein Eng. 12, 491–496.
Jackson, M. & Mantsch, H. H. (1995). Crit. Rev. Biochem. Mol. Biol.
30, 95–120.
Janin, J., Miller, S. & Chothia, C. (1988). J. Mol. Biol. 204, 155–164.
Janin, J. & Rodier, F. (1995). Proteins, 23, 580–587.
Johnson, C. S. & Gabriel, D. A. (1994). Laser Light Scattering. New
York: Dover.
Kelly, S. M. & Price, N. C. (2000). Curr. Protein Pept. Sci. 1, 349–384.
Lakowitz, J. R. (2006). Principles of Fluorescence Spectroscopy.
Berlin: Springer.
Lebowitz, J., Lewis, M. S. & Schuck, P. (2002). Protein Sci. 11, 2067–
2079.
Lucas, L. H., Yan, J., Larive, C. K., Zartler, E. R. & Shapiro, M. J.
(2003). Anal. Chem. 75, 627–634.
Mikol, V., Hirsch, E. & Giege ´, R. (1990). J. Mol. Biol. 213, 187–
195.
Millard, T. H., Bompard, G., Heung, M. Y., Dafforn, T. R., Scott, D. J.,
Machesky, L. M. & Fu ¨tterer, K. (2005). EMBO J. 24, 240–250.
Minton, A. P. (2000). Exp. Mol. Med. 32, 1–5.
Misenheimer, T. M., Hannah, B. L., Annis, D. S. & Mosher, D. F.
(2003). Biochemistry, 42, 5125–5132.
Owen, D. J., Vallis, Y., Noble, M. E., Hunter, J. B., Dafforn, T. R.,
Evans, P. R. & McMahon, H. T. (1999). Cell, 97, 805–815.
Patel, H. V., Vyas, K. A., Savtchenko, R. & Roseman, S. (2006). J.
Biol. Chem. 281, 17570–17578.
Perugini, M. A., Grifﬁn, M. D., Smith, B. J., Webb, L. E., Davis, A. J.,
Handman, E. & Gerrard, J. A. (2005). Eur. Biophys. J. 34, 469–476.
Perutz, M. F. (1954). Proc. R. Soc. A, 225, 264–286.
Pusey, M. L., Liu, Z.-J., Tempel, W., Praissman, J., Lin, D., Wang,
B.-C., Gavira, J. A. & Ng, J. D. (2005). Prog. Biophys. Mol. Biol. 88,
359–386.
Robert, C. H. & Janin, J. (1998). J. Mol. Biol. 283, 1037–1047.
Schmitz, K. (1990). An Introduction to Dynamic Light Scattering by
Macromolecules. San Diego: Academic Press.
Schuster, T. M. & Toedt, J. M. (1996). Curr. Opin. Struct. Biol. 6,
650–658.
Sivasothy, P., Dafforn, T. R., Gettins, P. G. & Lomas, D. A. (2000). J.
Biol. Chem. 275, 33663–33668.
Skouri, M., Delsanti, M., Munch, J. P., Lorber, B. & Giege ´, R. (1991).
FEBS Lett. 295, 84–88.
Stratikos, E. & Gettins, P. G. (1997). Proc. Natl Acad. Sci. USA, 94,
453–458.
Stratikos, E. & Gettins, P. G. (1998). J. Biol. Chem. 273, 15582–15589.
Terwilliger, T. C. et al. (2003). Tuberculosis, 83, 223–249.
Wang, X. & Janin, J. (1993). Acta Cryst. D49, 505–512.
Wilson, W. W. (2003). J. Struct. Biol. 142, 56–65.
Winzor, D. J. (2003). J. Biochem. Biophys. Methods, 56, 15–52.
Yan, Y. & Marriott, G. (2003). Curr. Opin. Chem. Biol. 7, 635–640.
Zartler, E. R., Yan, J., Mo, H., Kline, A. D. & Shapiro, M. J. (2003).
Curr. Top. Med. Chem. 3, 25–37.
Zsila, F.,Bikadi, Z., Fitos, I. & Simonyi, M. (2004). Curr. Drug Discov.
Technol. 1, 133–153.
research papers
Acta Cryst. (2007). D63, 17–25 Dafforn   Protein complexes 25